{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:59:13Z","timestamp":1793383153935,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T00:00:00Z","timestamp":1616803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T00:00:00Z","timestamp":1616803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Key Research and Development Program of China","award":["No. 2016YFC0901505"],"award-info":[{"award-number":["No. 2016YFC0901505"]}]},{"name":"Beijing key laboratory of molecular diagnosis and study on pediatric genetic diseases","award":["BZ0317"],"award-info":[{"award-number":["BZ0317"]}]},{"name":"German Research Foundation DFG","award":["GR 1852\/6-1 to OG"],"award-info":[{"award-number":["GR 1852\/6-1 to OG"]}]},{"name":"German Federal Ministry of Education and Research","award":["01KG1104 to OG"],"award-info":[{"award-number":["01KG1104 to OG"]}]},{"name":"European Alport Registry is supported by the Association pour l\u2019Information et la Recherche sur les Maladies R\u00e9nales G\u00e9n\u00e9tiques","award":["AIRG-France"],"award-info":[{"award-number":["AIRG-France"]}]},{"name":"K. C. Wong Education Foundation and DAAD"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Autosomal recessive Alport syndrome (ARAS) is caused by pathogenic variants in both alleles of either <jats:italic>COL4A3<\/jats:italic> or <jats:italic>COL4A4<\/jats:italic> genes. Reports on ARAS are rare due to small patient numbers and there are no reports on renin-angiotensin-aldosterone system (RAAS) inhibition therapy in ARAS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Retrospective study in 101 patients with ARAS from Chinese Registry Database of Hereditary Kidney Diseases and European Alport Registry. Genotype\u2013phenotype correlations and nephroprotective effects of RAAS inhibition in ARAS were evaluated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Median age was 15 years (range 1.5\u201346 years). Twelve patients progressed to stage 5 chronic kidney disease (CKD5) at median age 20.5 years. Patients without missense variants had both higher prevalence and earlier onset age of hearing loss, nephrotic-range proteinuria, more rapid decline of eGFR, and earlier onset age of CKD5 compared to patients with 1 or 2 missense variants. Most patients (79\/101, 78%) currently are treated with RAAS inhibitors; median age at therapy initiation was 10 years and mean duration 6.5 \u00b1 6.0 years. Median age at CKD5 for untreated patients was 24 years. RAAS inhibition therapy delayed CKD5 onset in those with impaired kidney function (T-III) to median age 35 years, but is undefined in treated patients with proteinuria (T-II) due to low number of events. No treated patients with microalbuminuria (T-I) progressed to CKD5. ARAS patients with 1 or 2 missense variants showed better response to treatment than patients with non-missense-variants.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our study provides the first evidence for early use of RAAS inhibition therapy in patients with ARAS. Furthermore, genotype in ARAS correlates with response to therapy in favor of missense variants.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00467-021-05040-9","type":"journal-article","created":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T00:04:42Z","timestamp":1616803482000},"page":"2719-2730","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Genotype\u2013phenotype correlations and nephroprotective effects of RAAS inhibition in patients with autosomal recessive Alport syndrome"],"prefix":"10.1007","volume":"36","author":[{"given":"Yanqin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"B\u00f6ckhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Rubel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,27]]},"reference":[{"key":"5040_CR1","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1681\/ASN.2012020148","volume":"24","author":"J Savige","year":"2013","unstructured":"Savige J, Gregory M, Gross O, Kashtan C, Ding J, Flinter F (2013) Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy. J Am Soc Nephrol 24:364\u2013375","journal-title":"J Am Soc Nephrol"},{"key":"5040_CR2","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/ki.2014.229","volume":"86","author":"JH Miner","year":"2014","unstructured":"Miner JH, Baigent C, Flinter F, Gross O, Judge P, Kashtan CE, Lagas S, Savige J, Blatt D, Ding J, Gale DP, Midgley JP, Povey S, Prunotto M, Renault D, Skelding J, Turner AN, Gear S (2014) The 2014 International Workshop on Alport Syndrome. Kidney Int 86:679\u2013684","journal-title":"Kidney Int"},{"key":"5040_CR3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s13023-018-0974-4","volume":"13","author":"X Zhang","year":"2018","unstructured":"Zhang X, Zhang Y, Zhang Y, Gu H, Chen Z, Ren L, Lu X, Chen L, Wang F, Liu Y, Ding J (2018) X-linked Alport syndrome: pathogenic variant features and further auditory genotype-phenotype correlations in males. Orphanet J Rare Dis 13:229","journal-title":"Orphanet J Rare Dis"},{"key":"5040_CR4","doi-asserted-by":"publisher","first-page":"703","DOI":"10.2215\/CJN.10581014","volume":"10","author":"J Savige","year":"2015","unstructured":"Savige J, Sheth S, Leys A, Nicholson A, Mack HG, Colville D (2015) Ocular features in Alport syndrome: pathogenesis and clinical significance. Clin J Am Soc Nephrol 10:703\u2013709","journal-title":"Clin J Am Soc Nephrol"},{"key":"5040_CR5","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1007\/s00467-017-3784-3","volume":"33","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Ding J (2018) Renal, auricular, and ocular outcomes of Alport syndrome and their current management. Pediatr Nephrol 33:1309\u20131316","journal-title":"Pediatr Nephrol"},{"key":"5040_CR6","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.jmoldx.2012.06.005","volume":"14","author":"F Wang","year":"2012","unstructured":"Wang F, Zhao D, Ding J, Zhang H, Zhang Y, Yu L, Xiao H, Yao Y, Zhong X, Wang S (2012) Skin biopsy is a practical approach for the clinical diagnosis and molecular genetic analysis of X-linked Alport\u2019s syndrome. J Mol Diagn 14:586\u2013593","journal-title":"J Mol Diagn"},{"key":"5040_CR7","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1681\/ASN.2012100985","volume":"24","author":"H Storey","year":"2013","unstructured":"Storey H, Savige J, Sivakumar V, Abbs S, Flinter FA (2013) COL4A3\/COL4A4 mutations and features in individuals with autosomal recessive Alport syndrome. J Am Soc Nephrol 24:1945\u20131954","journal-title":"J Am Soc Nephrol"},{"key":"5040_CR8","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1002\/ajmg.a.35528","volume":"158A","author":"Y Zhang","year":"2012","unstructured":"Zhang Y, Wang F, Ding J, Zhang H, Zhao D, Yu L, Xiao H, Yao Y, Zhong X, Wang S (2012) Genotype-phenotype correlations in 17 Chinese patients with autosomal recessive Alport syndrome. Am J Med Genet A 158A:2188\u20132193","journal-title":"Am J Med Genet A"},{"key":"5040_CR9","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s00467-014-2797-4","volume":"29","author":"M Oka","year":"2014","unstructured":"Oka M, Nozu K, Kaito H, Fu XJ, Nakanishi K, Hashimura Y, Morisada N, Yan K, Matsuo M, Yoshikawa N, Vorechovsky I, Iijima K (2014) Natural history of genetically proven autosomal recessive Alport syndrome. Pediatr Nephrol 29:1535\u20131544","journal-title":"Pediatr Nephrol"},{"key":"5040_CR10","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/cge.12258","volume":"86","author":"C Fallerini","year":"2014","unstructured":"Fallerini C, Dosa L, Tita R, Del Prete D, Feriozzi S, Gai G, Clementi M, La Manna A, Miglietti N, Mancini R, Mandrile G, Ghiggeri GM, Piaggio G, Brancati F, Diano L, Frate E, Pinciaroli AR, Giani M, Castorina P, Bresin E, Giachino D, De Marchi M, Mari F, Bruttini M, Renieri A, Ariani F (2014) Unbiased next generation sequencing analysis confirms the existence of autosomal dominant Alport syndrome in a relevant fraction of cases. Clin Genet 86:252\u2013257","journal-title":"Clin Genet"},{"key":"5040_CR11","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1681\/ASN.2013080912","volume":"25","author":"V Morini\u00e8re","year":"2014","unstructured":"Morini\u00e8re V, Dahan K, Hilbert P, Lison M, Lebbah S, Topa A, Bole-Feysot C, Pruvost S, Nitschke P, Plaisier E, Knebelmann B, Macher MA, Noel LH, Gubler MC, Antignac C, Heidet L (2014) Improving mutation screening in familial hematuric nephropathies through next generation sequencing. J Am Soc Nephrol 25:2740\u20132751","journal-title":"J Am Soc Nephrol"},{"key":"5040_CR12","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/cge.12919","volume":"92","author":"C Fallerini","year":"2017","unstructured":"Fallerini C, Baldassarri M, Trevisson E, Morbidoni V, La Manna A, Lazzarin R, Pasini A, Barbano G, Pinciaroli AR, Garosi G, Frullanti E, Pinto AM, Mencarelli MA, Mari F, Renieri A, Ariani F (2017) Alport syndrome: impact of digenic inheritance in patients management. Clin Genet 92:34\u201344","journal-title":"Clin Genet"},{"key":"5040_CR13","doi-asserted-by":"publisher","first-page":"e647","DOI":"10.1002\/mgg3.647","volume":"7","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Ding J, Zhang H, Yao Y, Xiao H, Wang S, Wang F (2019) Effect of heterozygous pathogenic COL4A3 or COL4A4 variants on patients with X-linked Alport syndrome. Mol Genet Genomic Med 7:e647","journal-title":"Mol Genet Genomic Med"},{"key":"5040_CR14","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1681\/ASN.V114649","volume":"11","author":"JP Jais","year":"2000","unstructured":"Jais JP, Knebelmann B, Giatras I, De Marchi M, Rizzoni G, Renieri A, Weber M, Gross O, Netzer KO, Flinter F, Pirson Y, Verellen C, Wieslander J, Persson U, Tryggvason K, Martin P, Hertz JM, Schr\u00f6der C, Sanak M, Krejcova S, Carvalho MF, Saus J, Antignac C, Smeets H, Gubler MC (2000) X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males. J Am Soc Nephrol 11:649\u2013657","journal-title":"J Am Soc Nephrol"},{"key":"5040_CR15","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1093\/ndt\/17.7.1218","volume":"17","author":"O Gross","year":"2002","unstructured":"Gross O, Netzer KO, Lambrecht R, Seibold S, Weber M (2002) Meta-analysis of genotype-phenotype correlation in X-linked Alport syndrome: impact on clinical counselling. Nephrol Dial Transplant 17:1218\u20131227","journal-title":"Nephrol Dial Transplant"},{"key":"5040_CR16","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1681\/ASN.2018030228","volume":"29","author":"T Horinouchi","year":"2018","unstructured":"Horinouchi T, Nozu K, Yamamura T, Minamikawa S, Omori T, Nakanishi K, Fujimura J, Ashida A, Kitamura M, Kawano M, Shimabukuro W, Kitabayashi C, Imafuku A, Tamagaki K, Kamei K, Okamoto K, Fujinaga S, Oka M, Igarashi T, Miyazono A, Sawanobori E, Fujimaru R, Nakanishi K, Shima Y, Matsuo M, Ye MJ, Nozu Y, Morisada N, Kaito H, Iijima K (2018) Detection of splicing abnormalities and genotype-phenotype correlation in X-linked Alport syndrome. J Am Soc Nephrol 29:2244\u20132254","journal-title":"J Am Soc Nephrol"},{"key":"5040_CR17","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3390\/jcm8020178","volume":"8","author":"JM Lee","year":"2019","unstructured":"Lee JM, Nozu K, Choi DE, Kang HG, Ha IS, Cheong HI (2019) Features of autosomal recessive Alport syndrome: a systematic review. J Clin Med 8:178","journal-title":"J Clin Med"},{"key":"5040_CR18","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1046\/j.1523-1755.2003.00779.x","volume":"63","author":"O Gross","year":"2003","unstructured":"Gross O, Beirowski B, Koepke ML, Kuck J, Reiner M, Addicks K, Smyth N, Schulze-Lohoff E, Weber M (2003) Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome. Kidney Int 63:438\u2013446","journal-title":"Kidney Int"},{"key":"5040_CR19","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/ki.2011.407","volume":"81","author":"O Gross","year":"2012","unstructured":"Gross O, Licht C, Anders HJ, Hoppe B, Beck B, T\u00f6nshoff B, H\u00f6cker B, Wygoda S, Ehrich JH, Pape L, Konrad M, Rascher W, D\u00f6tsch J, M\u00fcller-Wiefel DE, Hoyer P, Study Group Members of the Gesellschaft f\u00fcr P\u00e4diatrische Nephrologie, Knebelmann B, Pirson Y, Grunfeld JP, Niaudet P, Cochat P, Heidet L, Lebbah S, Torra R, Friede T, Lange K, M\u00fcller GA, Weber M (2012) Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int 81:494\u2013501","journal-title":"Kidney Int"},{"key":"5040_CR20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00467-012-2138-4","volume":"28","author":"CE Kashtan","year":"2013","unstructured":"Kashtan CE, Ding J, Gregory M, Gross O, Heidet L, Knebelmann B, Rheault M, Licht C, Alport Syndrome Research Collaborative (2013) Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative. Pediatr Nephrol 28:5\u201311","journal-title":"Pediatr Nephrol"},{"key":"5040_CR21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00467-015-3184-5","volume":"31","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Wang F, Ding J, Zhang H, Liu X, Wang S, Xiao H, Yao Y, Liu J, Zhong X, Guan N, Su B, Wu G, Yu L (2016) Long-term treatment by ACE inhibitors and angiotensin receptor blockers in children with Alport syndrome. Pediatr Nephrol 31:67\u201372","journal-title":"Pediatr Nephrol"},{"key":"5040_CR22","first-page":"916","volume":"32","author":"O Gross","year":"2017","unstructured":"Gross O, Kashtan CE, Rheault MN, Flinter F, Savige J, Miner JH, Torra R, Ars E, Deltas C, Savva I, Perin L, Renieri A, Ariani F, Mari F, Baigent C, Judge P, Knebelman B, Heidet L, Lagas S, Blatt D, Ding J, Zhang Y, Gale DP, Prunotto M, Xue Y, Schachter AD, Morton LCG, Blem J, Huang M, Liu S, Vallee S, Renault D, Schifter J, Skelding J, Gear S, Friede T, Turner AN, Lennon R (2017) Advances and unmet needs in genetic, basic and clinical science in Alport syndrome: report from the 2015 International Workshop on Alport Syndrome. Nephrol Dial Transplant 32:916\u2013924","journal-title":"Nephrol Dial Transplant"},{"key":"5040_CR23","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s00467-018-3985-4","volume":"34","author":"J Savige","year":"2019","unstructured":"Savige J, Ariani F, Mari F, Bruttini M, Renieri A, Gross O, Deltas C, Flinter F, Ding J, Gale DP, Nagel M, Yau M, Shagam L, Torra R, Ars E, Hoefele J, Garosi G, Storey H (2019) Expert consensus guidelines for the genetic diagnosis of Alport syndrome. Pediatr Nephrol 34:1175\u20131189","journal-title":"Pediatr Nephrol"},{"key":"5040_CR24","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL, ACMG Laboratory Quality Assurance Committee (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17:405\u2013424","journal-title":"Genet Med"},{"key":"5040_CR25","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1007\/s00467-006-0393-y","volume":"22","author":"K Rana","year":"2007","unstructured":"Rana K, Tonna S, Wang YY, Sin L, Lin T, Shaw E, Mookerjee I, Savige J (2007) Nine novel COL4A3 and COL4A4 mutations and polymorphisms identified in inherited membrane diseases. Pediatr Nephrol 22:652\u2013657","journal-title":"Pediatr Nephrol"},{"key":"5040_CR26","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/cge.12247","volume":"86","author":"BD Webb","year":"2014","unstructured":"Webb BD, Brandt T, Liu L, Jalas C, Liao J, Fedick A, Linderman MD, Diaz GA, Kornreich R, Trachtman H, Mehta L, Edelmann L (2014) A founder mutation in COL4A3 causes autosomal recessive Alport syndrome in the Ashkenazi Jewish population. Clin Genet 86:155\u2013160","journal-title":"Clin Genet"},{"key":"5040_CR27","doi-asserted-by":"publisher","first-page":"e71381","DOI":"10.1371\/journal.pone.0071381","volume":"8","author":"M Miyagawa","year":"2013","unstructured":"Miyagawa M, Naito T, Nishio SY, Kamatani N, Usami S (2013) Targeted exon sequencing successfully discovers rare causative genes and clarifies the molecular epidemiology of Japanese deafness patients. PLoS One 8:e71381","journal-title":"PLoS One"},{"key":"5040_CR28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1681\/ASN.V12197","volume":"12","author":"L Heidet","year":"2001","unstructured":"Heidet L, Arrondel C, Forestier L, Cohen-Solal L, Mollet G, Gutierrez B, Stavrou C, Gubler MC, Antignac C (2001) Structure of the human type IV collagen gene COL4A3 and mutations in autosomal Alport syndrome. J Am Soc Nephrol 12:97\u2013106","journal-title":"J Am Soc Nephrol"},{"key":"5040_CR29","doi-asserted-by":"publisher","first-page":"e0161802","DOI":"10.1371\/journal.pone.0161802","volume":"11","author":"J Savige","year":"2016","unstructured":"Savige J, Storey H, Il Cheong H, Gyung Kang H, Park E, Hilbert P, Persikov A, Torres-Fernandez C, Ars E, Torra R, Hertz JM, Thomassen M, Shagam L, Wang D, Wang Y, Flinter F, Nagel M (2016) X-linked and autosomal recessive Alport syndrome: pathogenic variant features and further genotype-phenotype correlations. PLoS One 11:e0161802","journal-title":"PLoS One"},{"key":"5040_CR30","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/j.1440-1797.2010.01438.x","volume":"16","author":"H Zhang","year":"2011","unstructured":"Zhang H, Ding J, Wang F, Zhao D (2011) Mutation detection of COL4An gene based on mRNA of peripheral blood lymphocytes and prenatal diagnosis of Alport syndrome in China. Nephrology 16:377\u2013380","journal-title":"Nephrology"},{"key":"5040_CR31","doi-asserted-by":"publisher","first-page":"e0177685","DOI":"10.1371\/journal.pone.0177685","volume":"12","author":"JH Liu","year":"2017","unstructured":"Liu JH, Wei XX, Li A, Cui YX, Xia XY, Qin WS, Zhang MC, Gao EZ, Sun J, Gao CL, Liu FX, Wu QY, Li WW, Asan LZH, Li XJ (2017) Novel mutations in COL4A3, COL4A4, and COL4A5 in Chinese patients with Alport syndrome. PLoS One 12:e0177685","journal-title":"PLoS One"},{"key":"5040_CR32","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.ajkd.2003.08.002","volume":"42","author":"B Taz\u00f3n Vega","year":"2003","unstructured":"Taz\u00f3n Vega B, Badenas C, Ars E, Lens X, Mil\u00e0 M, Darnell A, Torra R (2003) Autosomal recessive Alport\u2019s syndrome and benign familial hematuria are collagen type IV diseases. Am J Kidney Dis 42:952\u2013959","journal-title":"Am J Kidney Dis"},{"key":"5040_CR33","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1159\/000107666","volume":"27","author":"P Hou","year":"2007","unstructured":"Hou P, Chen Y, Ding J, Li G, Zhang H (2007) A novel mutation of COL4A3 presents a different contribution to Alport syndrome and thin basement membrane nephropathy. Am J Nephrol 27:538\u2013544","journal-title":"Am J Nephrol"},{"key":"5040_CR34","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1093\/hmg\/3.8.1269","volume":"3","author":"HH Lemmink","year":"1994","unstructured":"Lemmink HH, Mochizuki T, van den Heuvel LP, Schr\u00f6der CH, Barrientos A, Monnens LA, van Oost BA, Brunner HG, Reeders ST, Smeets HJ (1994) Mutations in the type IV collagen alpha 3 (COL4A3) gene in autosomal recessive Alport syndrome. Hum Mol Genet 3:1269\u20131273","journal-title":"Hum Mol Genet"},{"key":"5040_CR35","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2215\/CJN.04120417","volume":"13","author":"JK Warejko","year":"2018","unstructured":"Warejko JK, Tan W, Daga A, Schapiro D, Lawson JA, Shril S, Lovric S, Ashraf S, Rao J, Hermle T, Jobst-Schwan T, Widmeier E, Majmundar AJ, Schneider R, Gee HY, Schmidt JM, Vivante A, van der Ven AT, Ityel H, Chen J, Sadowski CE, Kohl S, Pabst WL, Nakayama M, Somers MJG, Rodig NM, Daouk G, Baum M, Stein DR, Ferguson MA, Traum AZ, Soliman NA, Kari JA, El Desoky S, Fathy H, Zenker M, Bakkaloglu SA, M\u00fcller D, Noyan A, Ozaltin F, Cadnapaphornchai MA, Hashmi S, Hopcian J, Kopp JB, Benador N, Bockenhauer D, Bogdanovic R, Staji\u0107 N, Chernin G, Ettenger R, Fehrenbach H, Kemper M, Munarriz RL, Podracka L, B\u00fcscher R, Serdaroglu E, Tasic V, Mane S, Lifton RP, Braun DA, Hildebrandt F (2018) Whole exome sequencing of patients with steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol 13:53\u201362","journal-title":"Clin J Am Soc Nephrol"},{"key":"5040_CR36","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1086\/302106","volume":"63","author":"E Boye","year":"1998","unstructured":"Boye E, Mollet G, Forestier L, Cohen-Solal L, Heidet L, Cochat P, Gr\u00fcnfeld JP, Palcoux JB, Gubler MC, Antignac C (1998) Determination of the genomic structure of the COL4A4 gene and of novel mutations causing autosomal recessive Alport syndrome. Am J Hum Genet 63:1329\u20131340","journal-title":"Am J Hum Genet"},{"key":"5040_CR37","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1093\/jmcb\/mju040","volume":"6","author":"J Xie","year":"2014","unstructured":"Xie J, Wu X, Ren H, Wang W, Wang Z, Pan X, Hao X, Tong J, Ma J, Ye Z, Meng G, Zhu Y, Kiryluk K, Kong X, Hu L, Chen N (2014) COL4A3 mutations cause focal segmental glomerulosclerosis. J Mol Cell Biol 6:498\u2013505","journal-title":"J Mol Cell Biol"},{"key":"5040_CR38","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/ncpneph0025","volume":"1","author":"A Meyrier","year":"2005","unstructured":"Meyrier A (2005) Mechanisms of disease: focal segmental glomerulosclerosis. Nat Clin Pract Nephrol 1:44\u201354","journal-title":"Nat Clin Pract Nephrol"},{"key":"5040_CR39","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.1681\/ASN.2007040444","volume":"18","author":"K Voskarides","year":"2007","unstructured":"Voskarides K, Damianou L, Neocleous V, Zouvani I, Christodoulidou S, Hadjiconstantinou V, Ioannou K, Athanasiou Y, Patsias C, Alexopoulos E, Pierides A, Kyriacou K, Deltas C (2007) COL4A3\/COL4A4 mutations producing focal segmental glomerulosclerosis and renal failure in thin basement membrane nephropathy. J Am Soc Nephrol 18:3004\u20133016","journal-title":"J Am Soc Nephrol"},{"key":"5040_CR40","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1093\/ndt\/gfv325","volume":"31","author":"C Gast","year":"2016","unstructured":"Gast C, Pengelly RJ, Lyon M, Bunyan DJ, Seaby EG, Graham N, Venkat-Raman G, Ennis S (2016) Collagen (COL4A) mutations are the most frequent mutations underlying adult focal segmental glomerulosclerosis. Nephrol Dial Transplant 31:961\u2013970","journal-title":"Nephrol Dial Transplant"},{"key":"5040_CR41","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.humpath.2018.02.024","volume":"81","author":"G Vischini","year":"2018","unstructured":"Vischini G, Kapp ME, Wheeler FC, Hopp L, Fogo AB (2018) A unique evolution of the kidney phenotype in a patient with autosomal recessive Alport syndrome. Hum Pathol 81:229\u2013234","journal-title":"Hum Pathol"},{"key":"5040_CR42","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3389\/fped.2018.00171","volume":"6","author":"MC Braunisch","year":"2018","unstructured":"Braunisch MC, B\u00fcttner-Herold M, G\u00fcnthner R, Satanovskij R, Riedhammer KM, Herr PM, Klein HG, Wahl D, K\u00fcchle C, Renders L, Heemann U, Schmaderer C, Hoefele J (2018) Heterozygous COL4A3 variants in histologically diagnosed focal segmental glomerulosclerosis. Front Pediatr 6:171","journal-title":"Front Pediatr"},{"key":"5040_CR43","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.kint.2017.12.018","volume":"93","author":"CE Kashtan","year":"2018","unstructured":"Kashtan CE, Ding J, Garosi G, Heidet L, Massella L, Nakanishi K, Nozu K, Renieri A, Rheault M, Wang F, Gross O (2018) Alport syndrome: a unified classification of genetic disorders of collagen IV \u03b1345: a position paper of the Alport Syndrome Classification Working Group. Kidney Int 93:1045\u20131051","journal-title":"Kidney Int"},{"key":"5040_CR44","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1016\/j.kint.2020.06.038","volume":"98","author":"T Yamamura","year":"2020","unstructured":"Yamamura T, Horinouchi T, Nagano C, Omori T, Sakakibara N, Aoto Y, Ishiko S, Nakanishi K, Shima Y, Nagase H, Takeda H, Rossanti R, Ye MJ, Nozu Y, Ishimori S, Ninchoji T, Kaito H, Morisada N, Iijima K, Nozu K (2020) Genotype-phenotype correlations influence the response to angiotensin-targeting drugs in Japanese patients with male X-linked Alport syndrome. Kidney Int 98:1605\u20131614","journal-title":"Kidney Int"},{"key":"5040_CR45","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00467-018-4121-1","volume":"35","author":"J Savige","year":"2020","unstructured":"Savige J (2020) Alport syndrome: deducing the mode of inheritance from the presence of haematuria in family members. Pediatr Nephrol 35:59\u201366","journal-title":"Pediatr Nephrol"},{"key":"5040_CR46","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/ki.2011.452","volume":"81","author":"J Temme","year":"2012","unstructured":"Temme J, Peters F, Lange K, Pirson Y, Heidet L, Torra R, Grunfeld JP, Weber M, Licht C, M\u00fcller GA, Gross O (2012) Incidence of renal failure and nephroprotection by RAAS inhibition in heterozygous carriers of X-chromosomal and autosomal recessive Alport mutations. Kidney Int 81:779\u2013783","journal-title":"Kidney Int"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-021-05040-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-021-05040-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-021-05040-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T10:11:09Z","timestamp":1629195069000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-021-05040-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,27]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["5040"],"URL":"https:\/\/doi.org\/10.1007\/s00467-021-05040-9","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,27]]},"assertion":[{"value":"21 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}